Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
A Sanofi-sponsored post hoc analysis of the LixiLan-L-CN trial reports that iGlarLixi lowered residual hyperglycaemia more than insulin glargine alone in Chinese adults with type 2 diabetes. PICO summary and expert commentary.
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide's effect in high-risk type 2 diabetes. PICO summary and expert commentary.
The ARIADNE non-inferiority trial tested whether a supported total diet replacement programme worsened eating disorder symptoms in adults with type 2 diabetes at high risk. PICO summary and expert commentary.
A Phase 2 randomised trial in 145 adults found once-weekly ecnoglutide lowered HbA1c by up to 2.39% versus 0.55% with placebo over 20 weeks. PICO summary and expert commentary.
A double-blind RCT testing whether the Omentin-1 Val109Asp genotype modifies vitamin D's effects on HDL-C, insulin resistance and abdominal obesity in prediabetic women. PICO summary and expert commentary.
A SURMOUNT-2 subpopulation analysis of 41 Japanese adults with type 2 diabetes and obesity, in which once-weekly tirzepatide produced significant 72-week weight loss versus placebo, tempered by a very small sample. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China asked whether baseline traits modify the glycaemic effect of once-weekly semaglutide versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
A mixed-methods comparison of 76 primary care practices found that having a diabetes care and education specialist was the only characteristic distinguishing those that chose self-paced versus virtually supported CGM implementation. PICO summary and expert commentary.
A small double-blind RCT in 38 patients with type 2 diabetes and coronary disease found pre-operative liraglutide gave better intra-operative glucose control and described regional epicardial fat microRNA patterns. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
